Differentiated Thyroid Carcinoma After Iodine-131 Metaiodobenzylguanidine Treatment for Neuroblastoma: Assessment of Causality

被引：2
|
作者：
Teszler, Chris Barna [1 ,2 ]
机构：
[1] Technion Israel Inst Technol, Bnai Zion MC, Bruce Rappaport Fac Med, IL-33394 Haifa, Israel
[2] Univ Freiburg, Dept Otolaryngol, D-79106 Freiburg, Germany
来源：
THYROID | 2013年 / 23卷 / 02期
关键词：
CHILDHOOD-CANCER; RISK; RADIOTHERAPY; COHORT;
D O I：
10.1089/thy.2012.0149
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：248 / 249
页数：2
相关论文
共 50 条
  • [1] Differentiated Thyroid Carcinoma After Iodine-131 Metaiodobenzylguanidine Treatment for Neuroblastoma: Assessment of Causality Response
    van Santen, Hanneke M.
    Tytgat, Godelieve A. M.
    de Wetering, Marianne D. van
    van Eck-Smit, Berthe L. F.
    Hopman, Saskia M. J.
    van der Steeg, Alida F.
    van Dijkum, Els J. M. Nieveen
    van Trotsenburg, A. S. Paul
    [J]. THYROID, 2013, 23 (02) : 249 - 249
  • [2] Sequential biological dosimetry after a single treatment with iodine-131 for differentiated thyroid carcinoma
    MKacher, R
    Legal, JD
    Schlumberger, M
    Aubert, B
    BeronGaillard, N
    Gaussen, A
    Parmentier, C
    [J]. JOURNAL OF NUCLEAR MEDICINE, 1997, 38 (03) : 377 - 380
  • [3] Study on the immunosuppression effects after iodine-131 treatment in patients with differentiated thyroid carcinoma
    Luo, QY
    Yu, YL
    Chen, LB
    Lu, HK
    Zhu, RS
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 : S426 - S427
  • [4] Adverse effects of radioactive iodine-131 treatment for differentiated thyroid carcinoma
    Fard-Esfahani, Armaghan
    Emami-Ardekani, Alireza
    Fallahi, Babak
    Fard-Esfahani, Pezhman
    Beiki, Davood
    Hassanzadeh-Rad, Arman
    Eftekhari, Mohammad
    [J]. NUCLEAR MEDICINE COMMUNICATIONS, 2014, 35 (08) : 808 - 817
  • [5] Predicting the efficacy of first iodine-131 treatment in differentiated thyroid carcinoma
    Muratet, JP
    Giraud, P
    Daver, A
    Minier, JF
    Gamelin, E
    Larra, F
    [J]. JOURNAL OF NUCLEAR MEDICINE, 1997, 38 (09) : 1362 - 1368
  • [6] Iodine-131 metaiodobenzylguanidine (131I-mIBG) treatment in relapsed/refractory neuroblastoma
    Anongpornjossakul, Yoch
    Sriwatcharin, Wattanun
    Thamnirat, Kanungnij
    Chamroonrat, Wichana
    Kositwattanarerk, Arpakorn
    Utamakul, Chirawat
    Sritara, Chanika
    Chokesuwattanasakul, Payap
    Thokanit, Nintita Sripaiboonkij
    Pakakasama, Samart
    Anurathapan, Usanarat
    Pongphitcha, Pongpak
    Chotipanich, Chanisa
    Hongeng, Suradej
    [J]. NUCLEAR MEDICINE COMMUNICATIONS, 2020, 41 (04) : 336 - 343
  • [7] Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma
    Leger, FA
    Izembart, M
    Dagousset, F
    Barritault, L
    Baillet, G
    Chevalier, A
    Clerc, J
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1998, 25 (03) : 242 - 246
  • [8] Conception after iodine-131 therapy for differentiated thyroid cancer
    Ayala, C
    Navarro, E
    Rodriguez, JR
    Silva, H
    Venegas, E
    Astorga, R
    [J]. THYROID, 1998, 8 (11) : 1009 - 1011
  • [9] Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma
    Françoise Aubène Leger
    Mireille Izembart
    Françoise Dagousset
    Lionel Barritault
    Georges Baillet
    Alain Chevalier
    Jérôme Clerc
    [J]. European Journal of Nuclear Medicine, 1998, 25 : 242 - 246
  • [10] Iodine-131 whole-body scintigraphy differentiated thyroid carcinoma
    Verburg, Frederik A.
    Gruenwald, Frank
    Lassmann, Michael
    Haenscheid, Heribert
    Luster, Markus
    Dietlein, Markus
    [J]. NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2018, 57 (04): : 124 - 136
12345